JP Morgan Chase
FNCH

JP Morgan Chase’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

JP Morgan Chase’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-118
Closed -$18K – 7081
2022
Q1 		$18K Sell
118
-43
-27% -$9.92K ﹤0.01% 6094
2021
Q4 		$48K Buy
161
+7
+5% +$2.68K ﹤0.01% 5967
2021
Q3 		$60K Sell
154
-180
-54% -$76.7K ﹤0.01% 5774
2021
Q2 		$141K Buy
+334
New +$145K ﹤0.01% 5412

Other funds holding FNCH

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AMC
Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
TA
TRB Advisors New York $146M AUM 3.71% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

JP Morgan Chase's FNCH Position: Q2 2022 in Review

JP Morgan Chase sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2022, closing a stake of 118 shares — an estimated $18K sold.

JP Morgan Chase first reported a position in FNCH in Q2 2021 and held it in 4 quarters. The position peaked at $141K in Q2 2021. 46 funds tracked by Wall St. Rank hold FNCH as of Q2 2022.

  • JP Morgan Chase reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • JP Morgan Chase sold 118 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2022, an estimated $18K.
  • JP Morgan Chase first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • JP Morgan Chase's Finch Therapeutics Group, Inc. Common Stock position peaked at $141K in Q2 2021.
  • 46 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2022.

Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.